Introduction

Gastric outlet obstruction (GOO) can occur from malignant and benign etiologies. Prior to the identification of H. Pylori and the advent of proton pump inhibitors, peptic ulcer disease (PUD) was the most common cause of GOO [1,2]. Since then, however, malignant disease has become the leading etiology of GOO [3,4]. Nevertheless, GOO from benign etiologies remains an important and difficult to treat pathology that can occur secondary to different disease processes including PUD, acute and chronic pancreatitis, caustic injury from substance ingestion, NSAID-induced stricture, and Crohn’s disease [1,5]. In terms of management, endoscopic balloon dilation (EBD) has largely replaced surgery as the first line treatment [1].

ABSTRACT

Background and study aims Endoscopic ultrasound-guided gastroenterostomy (EUS-GE) in malignant gastric outlet obstruction (GOO) appears to be promising; however, its role in benign GOO is unclear. The aim of this study was to ascertain the clinical efficacy and safety of EUS-GE in benign GOO.

Patients and methods This was an international retrospective series involving 5 tertiary centers. Consecutive patients who underwent EUS-GE between 1/2013 – 10/2016 for benign GOO were included. The primary endpoint was the rate of clinical success defined as ability to tolerate oral intake without vomiting. Secondary endpoints included technical success and rate of adverse events (AE).

Results Overall, 26 patients (46.2 % female; mean age 57.7 ± 13.9 years) underwent EUS-GE for benign GOO due to strictures from chronic pancreatitis (n = 11), surgical anastomosis (n = 6), peptic ulcer disease (n = 5), acute pancreatitis (n = 1), superior mesentery artery syndrome (n = 1), caustic injury (n = 1), and hematoma (n = 1). Technical success was achieved in 96.2 %. Dilation of the lumen apposing metal stent was performed in 13/25 (52%) with a mean maximum diameter of 14.6 ± 1.0 mm. Mean procedure time was 44.6 ± 26.1 min. Clinical success was observed in 84.0 % with a mean time to oral intake of 1.4 ± 1.9 days and a median follow-up of 176.5 (IQR: 47 – 445.75) days. Rate of unplanned re-intervention was 4.8 %. 3 AE were noted including 2 misdeployed stents and 1 gastric leak needing surgical intervention following elective GE stent removal.

Conclusions EUS-GE is a promising treatment for benign GOO. Larger and prospective data are needed to further validate this novel endoscopic technique in treating benign GOO of various etiologies.
though, clinical success is high with EBD in peptic strictures, it frequently requires multiple endoscopy sessions with repeat dilations, a risk of perforation in 3–7%, and limited long-term response of 70–80% [1, 6–10]. In addition, EBD may be less successful in other diseases such as caustic injury [11, 12] and strictures secondary to pancreatitis due to more severe and extensive fibrostenotic changes [5]. Other treatment modalities such as enteral stenting are associated with limited data to support its regular use while surgery is invasive and associated with significant risk for surgical morbidity [1, 13–16].

Endoscopic ultrasound guided gastroenterostomy (EUS-GE) with a lumen apposing metal stent (LAMS) is a novel technique described in the management of GOO [17, 18]. It entails the insertion of the LAMS from the stomach to the small bowel distal to the obstruction, thereby effectively bypassing the luminal compromise [19]. Small retrospective and prospective series have shown promising results with high clinical success, safety, and low risk for stent obstruction [20–22]. However, the majority of the data on EUS-GE have involved patients with malignant GOO and its efficacy in benign disease is largely undefined. The primary aim of this international multicenter retrospective series is to ascertain the role of EUS-GE in benign GOO and its efficacy in benign disease is largely undefined. The primary aim of this international multicenter retrospective series is to ascertain the role of EUS-GE in benign GOO by looking at technical feasibility, clinical success, and safety.

Patients and methods

This is a retrospective multicenter study involving 5 centers (3 North America, 1 Europe, and 1 Asia). The institutional review board at each participating center approved this study. All consecutive patients who underwent EUS-GE for benign GOO between January 2014 and October 2016 were included. Patients were identified using center-specific endoscopic or billing databases. Patients with malignant GOO were excluded. Several patients in this study were individually reported in other separate publications but those were not focused on benign disease [18, 23]. Using electronic medical records, the following data were recorded: patient demographics, etiology of GOO, anatomic site of obstruction (categorized as prepyloric/pyloric, duodenal bulb, second part of duodenum, and descending duodenum), prior endoscopic stenting and/or dilation, total procedure time, type/size/number of stent(s) used, technical success, reasons for technical failure, EUS-GE technical approach, location of needle puncture, whether the LAMS was dilated post-insertion and caliber of dilation, procedure related adverse events (AEs) with severity graded per the American Society of Gastrointestinal Endoscopy (ASGE) lexicon [24], time to oral intake, type of diet tolerated after EUS-GE, post-procedure length of hospital stay, need for re-intervention, and total duration of follow-up.

Study endpoints

The primary endpoint was the rate of clinical success defined as ability to tolerate oral intake without vomiting. Diet tolerated was graded as 0 = no oral diet, 1 = liquids only, 2 = soft solids, 3 = almost complete diet, 4 = full diet [25]. Secondary endpoints include procedure time, rate of technical success defined as adequate positioning and deployment of the stent as determined endoscopically and radiographically, and rate of AEs with the severity graded per the ASGE Lexicon [24].

**EUS-GE techniques**

All patients received intravenous antibiotics immediately prior to the procedure. EUS-GE was performed in an endoscopy unit or in an operating room with general anesthesia and endotracheal intubation. Informed consent was obtained from all patients prior to the procedure. All EUS-GE were performed using therapeutic echoendoscopes by expert endoscopists at tertiary care centers with or without trainee involvement. Decision regarding whether or not subsequent stent removal was performed and timing of stent removal were at the discretion of the endoscopist based on patients’ clinical evolution. 1 of the following technical approaches was used (decision regarding the approach used was at the discretion of the endoscopist):

**Direct gastroenterostomy**

DGE entails direct puncture of a small bowel loop adjacent to the gastric wall using a therapeutic echoendoscope (Fig. 1). To facilitate the puncture, a forward-viewing gastroscope (GFQ180 or GFQ190, Olympus Corporation, Tokyo, Japan) is first inserted and fluid infused into the small bowel distal to the obstruction. Generally, a total of 500 ml of fluid using a combination of saline, methylene blue, and contrast is infused. A 19-gauge needle can then be used as a “finder” needle to locate a small bowel loop closest to the stomach with aspiration of blue-tinged fluid confirming the correct puncture site. The puncture position may then be confirmed via enterogram. The needle is withdrawn while keeping the endoscope in a stable position. A cautery-assisted LAMS (Axios stent, Boston Scientific Corporation Inc., Marlborough, MA, USA) is then inserted directly across the stomach and into the small bowel followed by stent deployment forming the gastroenterostomy.

**Balloon assisted gastroenterostomy**

The balloon assisted gastroenterostomy (BAGE) method has been developed with the hope of improving small bowel access and possibly facilitating stent insertion with the help of a guidewire. A stone retrieval or dilating balloon is inserted over a wire across the obstruction. Following inflation of the balloon with contrast fluid, EUS-guided puncture of the balloon is performed transgastrically with a 19-gauge needle. A guidewire is then advanced deep into the small bowel to guide subsequent insertion of a LAMS.

**EUS-guided double-balloon-occluded gastrojejunostomy bypass**

Recently, a specialized double-balloon enteric tube (Tokyo Medical University Type; Create Medic, Yokohama, Japan) has been introduced to facilitate EUS-GE [21, 26] but is not yet available outside Japan. The balloon delivery catheter is inserted over a wire across the obstruction. Water with contrast is then used to inflate both balloons to anchor and seal the small bowel at 2 ends. Saline is then infused generously between the 2 balloons. This water insufflation allows for approximation of
small bowel loop to the gastric wall leading to easier and safer transgastric EUS puncture and stent insertion with the cautery tip assisted LAMS.

Statistical analysis

Continuous variables were reported as means with standard deviations (SD) or, for skewed data, medians with interquartile ranges (IQR). Comparison of linear variables was performed with the t-test and categorical variables by using the chi-square test. A level of significance of \( P < 0.05 \) was adopted for all inferential testing. Statistical analysis was performed by using SPSS version 16 (SPSS Inc, Chicago, Ill).

Results

A total of 26 patients (46.2% female; mean age 57.7 ± 13.9 years) underwent EUS-GE for benign GOO due to strictures from chronic pancreatitis (n = 11, 42.3%), surgical anastomosis (n = 6, 23.1%), peptic ulcer disease (n = 5, 19.2%), acute pancreatitis (n = 1, 3.8%), superior mesentery artery syndrome due to severe anorexia from colorectal cancer (n = 1, 3.8%), caustic injury (n = 1, 3.8%), and duodenal wall hematoma from blunt abdominal wall injury (n = 1, 3.8%)(Table 1). In the 6 patients with surgical anastomosis the type of surgery and site of obstruction were: Billroth I for gastric cancer with stenosis at the gastroduodenal anastomosis n = 1, duodenal repair post ERCP perforation complicated by duodenal stricture n = 1, roux-en-y reconstruction with stricture at the gastrojejunostomy n = 2, proximal jejunal resection for neuroendocrine tumor complicated by proxima jejunal stricture n = 1, and undefined n = 1. Patients presented with predominant symptoms of nausea and vomiting or abdominal pain in 21 and 5 cases, respectively. The decision to proceed to EUS-GE in patients with conditions such as SMA syndrome, hematoma compression, and acute pancreatitis was due to failure of conservative approach with a feeding tube, severity of patients’ symptoms and predicted likelihood of prolonged obstruction. The site of GOO was prepyloric/pyloric in 10 (38.5%) patients, duodenal bulb in 4 (15.4%), second part of duodenum in 7 (26.9%), and descending duodenum in 5 (19.2%). A total of 11 (42.3%) patients had previous endoscopic therapy including 10 patients who underwent endoscopic balloon dilation (EBD), 3 patients who underwent both EBD and enteral stenting (ES), and 1 patient who underwent ES only. EUS-GE was performed as a first line treatment in 15 (56.7 %) of the patients. Reasons for proceeding directly to EUS-GE include high-grade obstruction with inability to traverse the obstruction with a guidewire to allow for EBD (n = 1) and GOO secondary to etiologies that are unlikely to respond to EBD (n = 2) or at risk of perforation due to ulceration (n = 2) near the stricture. The mean number of prior dilation sessions per patient was 2.2 ± 1.1 with a mean maximal dilation diameter of 18.5 ± 2.2 mm. In the 4 patients with previous enteral stenting, stent failure was due to stent migration (n = 1, esophageal partially covered stent Niti-S™, Taewoong Medical co,
South Korea) and stent obstruction (n = 3: LAMS n = 1, esophageal partially covered stent Niti-STM n = 2).

All EUS-GE procedures were performed with a 15-mm LAMS (cautery-assisted n = 24, non-cautery-assisted n = 2) with the direct approach (n = 15, 57.7%), balloon-assisted technique (n = 7, 26.9%), or the EPASS technique (n = 4, 15.4%) (▶ Table 2). Technical success was achieved in 25/26 (96.2%) cases and dilation of the LAMS performed in 13/25 (52%) with a mean max diameter of 14.6 ± 1.0 mm. The mean procedure time was 44.6 ± 26.1 minutes.

Clinical success was observed in 21/25 (84.0%) cases with a median follow-up duration of 176.5 (IQR: 47 – 445.75) days. Of those with clinical success, 66.7% (14/21) were able to tolerate a full diet, 14.2% (3/21) an almost complete diet, 4.8% (1/21) a soft diet, and 14.2% (3/21) a liquid diet. The mean time to per oral intake was 1.4 ± 1.9 days. Clinical failure occurred in 4 patients: 2 patients required the insertion of a percutaneous enteral gastrostomy with jejunostomy tube extension (PEG-J) for suspected gastroparesis, 1 patient had PEG insertion for decompensation of ileus, and 1 patient was managed surgically.

The latter had failed to respond clinically to the stent and following elective removal of the LAMS at 88 days post EUS-GE was discovered to have gastric leak. The patient underwent emergency laparoscopic gastric wedge resection and Billroth II reconstruction. The patient recovered uneventfully from the surgery and had resolution of the gastric outlet obstruction following resection of the obstructed pylorus secondary to a peptic stricture. The etiology of GOO in patients with clinical failures included peptic stricture (n = 2), chronic pancreatitis (n = 1), and superior mesenteric artery (SMA) syndrome (n = 1) (▶ Fig. 2). In terms of safety, there were 2 procedure related AEs, which were rated as mild in severity. These AEs were due to misdeployment of the LAMS with the distal end failing to anchor in the small bowel. Both cases were managed with insertion of a fully covered esophageal stent 18 × 60 mm (Niti-S™, Taewoong Medical co, Korea) through the LAMS to serve as a bridge during the index procedure. No further sequelae were seen in these 2 patients. As aforementioned, there was also a case of gastric leak needing surgical intervention following stent removal. This complication was rated as a severe AE.

In terms of reintervention, of the 21 patients with initial clinical success, unplanned reintervention was performed in only 1 (4.8%) patient due to stent obstruction secondary to food impaction. This was successfully managed with endoscopic stent cleaning. Overall, 2 patients underwent elective LAMS stent removal with 1 patient due to inadequate clinical response and the other following resolution of GOO due to a large hematoma that subsequently resolved. As aforementioned, the stent removal for the former was complicated by a gastric leak requiring surgery while the latter was uneventful with no observed AE.

Table 1. Baseline characteristics of patients undergoing EUS-GE for benign GOO.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean Age ± SD, years</td>
<td>57.7 ± 13.9</td>
</tr>
<tr>
<td>Female n (%)</td>
<td>12 (46.2)</td>
</tr>
<tr>
<td>Etiology n (%)</td>
<td></td>
</tr>
<tr>
<td>Chronic pancreatitis stricture</td>
<td>11 (42.3)</td>
</tr>
<tr>
<td>Surgical anastomosis stricture</td>
<td>6 (23.1)</td>
</tr>
<tr>
<td>Peptic stricture</td>
<td>5 (19.2)</td>
</tr>
<tr>
<td>Acute pancreatitis</td>
<td>1 (3.8)</td>
</tr>
<tr>
<td>Superior mesenteric syndrome</td>
<td>1 (3.8)</td>
</tr>
<tr>
<td>Caustic stricture</td>
<td>1 (3.8)</td>
</tr>
<tr>
<td>External compression from a hematoma</td>
<td>1 (3.8)</td>
</tr>
<tr>
<td>Location of the obstruction n (%)</td>
<td></td>
</tr>
<tr>
<td>Prepyloric/pyloric</td>
<td>10 (38.5)</td>
</tr>
<tr>
<td>Duodenal bulb</td>
<td>4 (15.4)</td>
</tr>
<tr>
<td>Second part of the duodenum</td>
<td>7 (26.9)</td>
</tr>
<tr>
<td>Descending duodenum</td>
<td>5 (19.2)</td>
</tr>
<tr>
<td>History of prior enteral stent n (%)</td>
<td>4 (15.4)</td>
</tr>
<tr>
<td>Mean number of previous enteral stents per patient</td>
<td>2.3 ± 1.3</td>
</tr>
<tr>
<td>Reason for enteral stent failure</td>
<td></td>
</tr>
<tr>
<td>Stent obstruction, n (%)</td>
<td>3 (75)</td>
</tr>
<tr>
<td>Stent migration, n (%)</td>
<td>1 (25)</td>
</tr>
<tr>
<td>History of prior dilation</td>
<td>10 (38.5)</td>
</tr>
<tr>
<td>Mean number of previous dilations ± SD</td>
<td>2.2 ± 1.1</td>
</tr>
<tr>
<td>Mean maximum dilation diameter (mm) ± SD</td>
<td>18.5 ± 2.2</td>
</tr>
</tbody>
</table>

Table 2. EUS-GE procedure characteristics.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean maximum dilation diameter (mm) ± SD</td>
<td>14.6 ± 1.0</td>
</tr>
</tbody>
</table>

1 Total number of patients = 26; EUS-GE, endoscopic ultrasound-guided gastroenterostomy; LAMS, lumen apposing metal stents; EPASS, EUS-guided double-balloon-occluded gastroenterostomy bypass.
Discussion

EUS-GE is a novel and promising modality in the management of GOO. It offers the potential benefits of a surgical bypass while maintaining a minimally invasive approach. Data supporting the use of EUS-GE, however, have largely focused on malignant GOO [20–22]. To our knowledge, this present study is the first published data aiming at ascertaining the role of EUS-GE in benign GOO. Overall, the rates of both technical and clinical success were 96.2% and 84.0% respectively, with 3 adverse events noted.

Benign GOO can arise from several etiologies with differing pathophysiology and response to treatment. Endoscopic balloon dilation (EBD) has largely replaced surgery as the initial treatment modality [1]. Clinical success with EBD, however, has been variable in the literature for benign disease. GOO secondary to PUD appears to have the highest response rate to EBD. In fact, 70–80% of patients can achieve long-term symptomatic relief with the combination of H. pylori eradication and EBD [1, 5–10]. However, limited non-surgical options are available in patients who fail EBD. In addition, EBD appears to be have limited effectiveness in other pathologies of benign GOO. In caustic injury induced GOO, for example, EBD requires more endoscopic sessions (range 2–13) and appears to be less effective in achieving long-term symptomatic relief [11, 12]. Structures associated with chronic pancreatitis can also be especially difficult to treat. In a series of 4 patients treated with EBD for chronic pancreatitis, all 4 patients failed to achieve symptomatic relief and underwent surgical intervention [27]. Poor response to EBD in pancreatitis was also noted in another small series where 50% of patients needed surgical intervention [28]. Extensive fibrosis and inflammation is believed to be the reason for the refractoriness to dilation. In addition, although generally safe, EBD has been associated with a perforation rate of 3–7% [1, 7, 10]. Enteral stenting has also been explored in the management of benign GOO. Although small series have shown promising results, stent migration occurs in up to 60% of the cases with fully covered metal stents, while uncovered metal stents are generally prohibited due to risk of permanent stent anchoring [13–16].

EUS-GE may be a promising modality in benign GOO especially in patients who have failed EBD, those with GOO etiologies that are unlikely to respond to dilation therapy, or when dilation is technically not possible, such as when the obstruction is not traversable with a guidewire. In our series, 84.0% of the patients achieved clinical success with EUS-GE with 42.3% of the patients having failed previous EBD and/or ES. Clinical success remained promising at 80.0% in patients with technically successful EUS-GE and failure with previous EBD and/or ES. The rate of unplanned re-intervention following initial clinical success was also low at 4.7%. This is in contrast to EBD, which often requires several endoscopic sessions to achieve the appropriate luminal diameter especially in non-peptic ulcer induced strictures [1, 6–10]. In addition, the clinical success of EUS-GE is unlikely to vary according to the etiology given that it is bypassing the anatomic site of obstruction instead of restoring luminal patency through the stricture. In terms of safety, there were 2 mild AEs due to stent misdeployment managed successfully with insertion of a bridging fully covered metal esophageal stents. In addition, there was 1 severe AE following elective stent removal resulting in a gastric leak needing emergency surgical management. To our knowledge, this is first reported case of gastric leak post stent removal for EUS-GE and there are currently no data in the literature looking at the safety of gastroenterostomy stent removal. Although EUS-GE is promising, it is important to keep in mind that it is still a developing technique in the management of benign GOO. The long-term effects of an indwelling LAMS and the safety of its removal are still to be further elucidated, while the technique remains to be perfected. Until further data is available, EUS-GE in benign GOO is best reserved for patients who have failed EBD or if EBD is not possible. It may also be considered in GOO etiologies that tend to have a poor response to dilation, such as strictures secondary to pancreatitis or caustic injury.

Our study is limited by its retrospective design. Consecutive patients were used to limit selection bias and although it is the largest and only series focused on benign GOO, it remains a
small study involving 26 patients. Also, follow-up time of 176.5 (IQR: 47 – 445.75) days is relatively short and longer follow-up data will be needed to ascertain the long-term clinical effectiveness and safety of EUS-GE. In addition, all procedures were performed by expert endoscopists at tertiary centers; therefore, our results may not be generalizable to community hospitals. As with any developing, novel technique, EUS-GE should be performed by experienced endoscopists at centers with the appropriate surgical and interventional radiology backup.

**Conclusion**

In conclusion, EUS-GE is a promising modality for the management of benign GOO caused by a variety of etiologies and may be especially useful in those who fail to respond to endoscopic balloon dilation. Questions regarding the safety of long-term stent indwelling and subsequent stent removal, however, remain to be elucidated. Larger studies and prospective data are needed to further validate this novel endoscopic technique in treating benign GOO.

**Competing interests**

Yen-I Chen is a consultant for Boston Scientific. Todd H. Baron is a consultant and speaker for Boston Scientific and Olympus. Rastislav Kunda is a consultant, speaker, and medical advisory board member for Boston Scientific and Omega medical Imaging. Jose Nieto is a consultant for Boston Scientific. Mouen A. Khashab is a consultant for Boston Scientific and Olympus.

**References**


CORRECTION
Chen Yi, James TW, Agarwal A et al. EUS-guided gastroenterostomy in management of benign gastric outlet obstruction
Endoscopy International Open 2018; 06: E363–E368.
DOI: 10.1055/s-0043-123468
In the above mentioned article was middle name of an author missing. Correct is: Theodore W. James